Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2021-12-20 00:00:00 ET · period of report 2021-12-17 · accession 0001562180-21-007810 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-20 | 2021-12-17 | SNDX | Morrison Briggs | CEO, Dir | S - Sale+OE | $20.00 | -35.2K | 48.3K | -42% | -$703.1K |
| D | 2021-12-20 | 2021-12-17 | SNDX | Morrison Briggs | CEO, Dir | M - OptEx | $10.90 | +35.2K | 83.5K | +73% | +$383.2K |
| D | 2021-12-20 | 2021-12-17 | SNDX | Morrison Briggs | CEO, Dir | M - OptEx | $0.00 | -35.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-17 | S | D | 35,156 | $20.00 | 48,336 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-17 | M | A | 35,156 | $10.90 | 83,492 | D | — | — | |
| 3 | Derivative | Stock Options (Right to buy) | 2021-12-17 | M | D | 35,156 | $0.00 | 0 | D | $10.90 · — to 2025-09-09 | 35,156 Common Stock | (F2) This option is fully vested. |